Stereotaxis ended September with $4.0 million of cash, then closed a $12 million convertible-note financing and obtained conditional access to another $12 million. Management describes the structure as a bridge to profitability. The financing improves immediate liquidity, but the second half is not cash on hand, and the 10% payment-in-kind interest makes execution time more expensive.
The judgment
- Implication: The initial closing materially reduces near-term cash pressure, but the bridge works only if commercial milestones arrive before compounded debt and possible dilution narrow the company’s choices.
- What would change the conclusion: Faster recurring-revenue growth, resolution of catheter supply constraints and evidence of sustained cash-burn improvement would support management’s bridge-to-profitability case. Delayed regulatory milestones, continued quarterly losses or another capital need would weaken it.
- Management action: Give the board a rolling cash forecast that separates the $12 million already closed from the conditional $12 million, shows accrued PIK interest and conversion dilution, and identifies the decision dates before liquidity becomes constrained.
What closed—and what did not
Stereotaxis’ November 10 Form 8-K says investors purchased $12 million of initial notes. The company may require up to another $12 million in as many as two additional closings, but only after specified regulatory conditions are satisfied. That distinction matters: $12 million is completed financing; the remaining $12 million is contingent availability.
The notes mature three years after issuance and carry 10% annual interest. Unless the parties agree otherwise, the interest is deferred and added to principal rather than paid in cash. Holders generally must consent to optional prepayment. The initial notes are convertible at $1.21 per share, a 30% premium to the preceding 10-day volume-weighted average price, subject to adjustment and ownership limits.
Payment-in-kind interest preserves cash now but increases the claim later. As a simple illustration—not a forecast of settlement or conversion—$12 million compounded annually at 10% would grow to about $16.0 million after three years if no interest were paid in cash. The actual outcome depends on conversion, timing and the note terms.
$4 million of cash explains the urgency
The company’s third-quarter results reported $8.9 million of revenue, a $6.5 million operating loss and $6.5 million of negative cash flow during the quarter. Of that cash use, management attributed $2.6 million to the core Stereotaxis business and $3.9 million to payments related to the Robocath acquisition.
After the initial note closing, management calculates pro forma cash of $16 million. It also describes total availability of $28 million by adding the conditional tranche. Those measures answer different questions. Pro forma cash estimates liquidity after a completed transaction; total availability includes funding that still depends on milestones.
This is the same distinction examined in PacBio Adds $100 Million of Equity Capacity to Its Runway: authorization or contractual capacity is not the same as cash already raised. For a small company with limited cash, the timing difference is especially important.
The profitability bridge needs an operating bridge
Management expects adjusted operating expenses of about $8 million per quarter and says revenue growth plus stable expenses provide a path to cash-flow profitability within the next year. That is a forward-looking estimate, not a reported result.
The operating case depends on several moving parts: installing commercial GenesisX systems, resolving MAGiC catheter supply constraints, expanding recurring catheter revenue and absorbing the Robocath acquisition. Third-quarter recurring revenue rose 6% from a year earlier but declined 4% sequentially, while recurring gross margin was 59% and system gross margin was 15%.
A useful bridge schedule would connect those operating milestones to cash. Each quarter should show starting unrestricted cash, expected receipts, operating and acquisition-related uses, PIK interest accrued, the earliest date the additional notes can be drawn and the downside case if a regulatory milestone slips. The free 13-Week Cash Flow Forecast illustrates the discipline: separate committed cash from expected cash and update the forecast before a shortfall becomes urgent.
Board-affiliated investors raise a governance question
The 8-K states that the accredited investors include entities affiliated with certain board members. That fact does not establish that the financing is unfair. It does mean the board should make the review process, conflicts and alternatives unusually clear.
- Which directors were treated as interested, and who evaluated the terms independently?
- What alternative financing structures were considered?
- How were the 10% rate, conversion premium and prepayment restriction benchmarked?
- How will the board monitor dilution and the conditions for drawing the second tranche?
As A Balanced Budget Can Still Hide a Cash Crisis explains, reported performance and available liquidity are different measures. Here, governance adds a third: a financing can be necessary and still require a rigorous conflict process.
The bottom line
Stereotaxis has secured meaningful time, but not a cost-free runway. The initial $12 million is real cash capacity; the second $12 million is milestone-dependent; and 10% PIK interest shifts today’s cash burden into a larger future claim. The financing succeeds if operating progress arrives before that claim becomes the next liquidity problem.

Leave a Reply